he prognosis of acute myocardial infarction (AMI) is greatly influenced by the time to recanalization after onset; the sooner the occluded coronary artery is reperfused, the smaller the infarct and the greater the preservation of cardiac function. Thus, the development of recanalization therapies that are faster and safer than the ones currently in use should provide better prognoses for AMI patients.Current recanalization therapy includes pharmacological thrombolysis and percutaneous coronary intervention (PCI), both of which have improved the prognoses of AMI patients. [1][2][3][4] In their current forms, however, each of these therapies has its limitations. For instance, PCI is time consuming and expensive, requiring transportation of patients to a specialized hospital at which cardiac catheterization can only be carried out by highly trained medical staff. On the other hand, intravenous pharmacological thrombolysis is noninvasive, less expensive and simpler than PCI, and can be started just after diagnosis of AMI, even in an ambulance. With this approach, however, Thrombolysis In Myocardial Circulation Journal Vol.71, October 2007 Infarction (TIMI) grade 3 flow is achieved in only 60-75% of patients. 5-8 Although a better reperfusion rate could be gained with higher doses of fibrinolytic agents, increasing the dose also makes hemorrhagic complications more likely. The next generation of thrombolytic therapies should be more rapid and produce higher rates of successful recanalization to TIMI grade 3 flow.Following the first report of using ultrasound (US) to induce thrombolysis, 9 many investigators began combining US with thrombolytic agents in an effort to enhance their efficacy. [10][11][12][13][14][15][16][17][18][19][20][21] It was found that US enables the dose of thrombolytic agent to be reduced and shortens the reperfusion time in experimental animals. Thus, a combination of US and a thrombolytic agent, such as tissue plasminogen activator (tPA), appears to be a promising approach to thrombolytic therapy. In those earlier studies, however, the thrombolytic effects of US were investigated using fibrin-rich thrombi, which are quite different from those responsible for AMI. In AMI, tissue factor-mediated platelet aggregation plays the crucial role in thrombogenesis; 22,23 consequently, the thrombi contain not only fibrin but also large numbers of platelets. 22,24 Therefore, to confirm the utility of US for lysis of platelet-rich thrombi, in vivo, we recently established a rabbit model of femoral artery occlusion in which platelet-rich arterial thrombi are acutely induced by repeated balloon injury. 25,26 We can then test whether US can enhance the pharmacological lysis of platelet-rich thrombi. Background Although sonothrombolysis has been studied for development of recanalization that is safer and more efficacious than the methods currently used, there have been no studies of the efficacy of sonothrombolysis for the platelet-rich thrombi that typically cause acute myocardial infarction (AMI). The e...